b3cnewswireJuly 01, 2021
Tag: Accelerate Diagnostics , AXDX , IOAS
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 9–12, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections.
The ePoster presentations are from real-world clinical use of the Accelerate Pheno system in diverse health systems and include endpoints for microbiology test turnaround time, antimicrobial use, and a subgroup analysis that measured 30-day mortality. The data further highlight the clinical benefits of using the Accelerate Pheno system, with significant improvements in multiple endpoints, including a statistically significant reduction in 30-day mortality in the Accelerate Pheno arm (AXDX) versus standard of care testing arm (SOC) in a subset of patients on ineffective empirical antibiotic treatment (6.0% in AXDX vs. 15.9% in SOC).
The Company’s presentations, which are available now on the ECCMID 2021 website, include:
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 661
ePoster Session: S147-3c
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 664
ePoster Session: S138-2b
Cedars-Sinai, University of Arkansas, Allegheny Health, University of Iowa
Abstract Number: 758
ePoster Session: S147-3c
Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1–2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
The “ACCELERATE DIAGNOSTICS” and “ACCELERATE PHENO” and “ACCELERATE PHENOTEST” and diamond shaped logos and marks are trademarks or registered trademarks of Accelerate Diagnostics, Inc.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: